Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy

Inclusion Criteria

• •Patients with potentially resectable adenocarcinoma of the stomach with histologic proof.
• •EUS or MRI stage T3-4, any N, M0.
• •Adequate bone marrow (defined as peripheral absolute granulocyte count of \> 2,000/μL, and platelet count of\>100,000/μL), liver (bilirubin \< 1.5 mg/dl), and renal functions (creatinine \< 1.5 mg/dl).
• •Absence of peritoneal disease by laparoscopic staging; no positive cytology of pleural, or pericardial effusion.
• •No prior major surgery or radiotherapy to the stomach, or immunotherapy or chemotherapy for any reason.
• •Patients must have a life expectancy of at least 16 weeks.
• •Performance status of \< 2 (Zubrod scale).
• •No biopsy proof of lymph node metastases outside the study field.
• •No evidence of metastatic disease to distant organs.
• •No presence of concurrent or previous malignancies \< 5 years, other than noninvasive skin cancer.
• •No uncontrolled or severe cardiac disease, diabetes or hypertension.
• •Signed study-specific consent form prior to study entry.